[1]. Shtivelman, E., et al., Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature, 1985. 315(6020): p. 550-4.
[2]. Kalmanti, L., et al., Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia, 2015. 29(5): p. 1123-32.
[3]. Buscarlet, M., et al., Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood, 2018. 132(3): p. 277-280.
[4]. Haferlach, T., et al., Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol, 1997. 97(1): p. 99-106.
[5]. Perna, F., et al., ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica, 2011. 96(2): p. 342-3.
[6]. Kakadia, P.M., et al., An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL. Leuk Res Rep, 2016. 6: p. 50-54.
[7]. Kawamata, N., et al., Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes Chromosomes Cancer, 2008. 47(10): p. 919-21.
[8]. Mori, N., et al., Translocation (9;12)(q34.1;p13.?3) Resulted in ETV6-ABL1 Fusion in a Patient with Philadelphia Chromosome-Negative Chronic Myelogenous Leukemia. Acta Haematol, 2016. 136(4): p. 240-243.
[9]. Kelly, J.C., et al., Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet, 2009. 192(1): p. 36-9.
[10]. O'Brien, S.G., et al., Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood, 2002. 99(9): p. 3465-7.
[11]. Barbouti, A., et al., Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol, 2003. 122(1): p. 85-93.
[12]. Gancheva, K., et al., Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review. Mol Cytogenet, 2013. 6(1): p. 39.
[13]. Nand, R., et al., Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res, 2009. 33(8): p. 1144-6.
[14]. Tiribelli, M., et al., Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement. Ann Hematol, 2015. 94(8): p. 1423-4.
[15]. Xie, W., et al., Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. Cancer Genet, 2018. 228-229: p. 41-46.
[16]. Choi, S.I., et al., A Case of Chronic Myeloid Leukemia With Rare Variant ETV6/ABL1 Rearrangement. Ann Lab Med, 2017. 37(1): p. 77-80.
[17]. Andreasson, P., et al., BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer, 1997. 20(3): p. 299-304.
[18]. Meyer-Monard, S., et al., Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia, 2005. 19(6): p. 1096-9.
[19]. Keung, Y.K., et al., Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet, 2002. 138(2): p. 139-42.
[20]. Van Limbergen, H., et al., Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer, 2001. 30(3): p. 274-82.
[21]. Mozziconacci, M.J., D. Sainty and C. Chabannon, A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome. Am J Hematol, 2007. 82(7): p. 688-9.